Ganciclovir
Ganciclovir has also been used with some success in treating "Human herpesvirus 6" infections.
Eliezer (Eli) Huberman
Huberman holds various patents including a series involving 5’-monophoshpate dehydrogenase, a target for the antiviral drug ribavirin, as well as one involving a class of drugs that in vitro are effective against human hepatitis C, immunodeficiency, corona and Ebola viruses.